US FDA Oncology Leadership Shuffle Moves Patricia Keegan To OCE; Gootenberg Takes On Recruitment
Executive Summary
US FDA's reorganization of drug reviews splits Keegan's old OHOP division into two.
You may also be interested in...
Oncology Center of Excellence Grows Leadership Structure, With A Vacancy Remaining
A deputy center director position remains open and four new associate director positions were added over the last year.
Drug Review Reorganization At US FDA Coming Into Focus
Oncology, neuroscience, and infectious diseases get acting directors as the expansion and renovation of the Office of New Drugs moves into Phase II.
Moving Beyond Aduhelm: Cell/Gene Therapy May Be ‘Poster Child’ For What Comes Next
Former FDA principal deputy commissioner Amy Abernethy says cell and gene therapy is an area primed for improved ‘parallel conversation’ between FDA and CMS on data requirements.